China News Service, August 29. On the 29th, the website of the State Food and Drug Administration issued a notice on the non-compliance of 20 batches of drugs.

The notice pointed out that 20 batches of medicines, including comfrey, which were marked as produced by 9 companies including Zhengzhou Ruilong Pharmaceutical Co., Ltd., were inspected by 6 drug inspection agencies including the China National Institute for Food and Drug Control and did not meet the requirements.

  The specific situation shows that the two batches of Dihyprophylline Injection, which were marked as produced by Shanxi Taiyuan Pharmaceutical Co., Ltd. (formerly Taiyuan Pharmaceutical Factory), were inspected by the Fujian Institute of Food and Drug Quality Inspection and were not in compliance with the regulations, and the non-compliance items were: Foreign bodies are visible.

  According to the inspection by Jilin Provincial Institute for Drug Inspection, one batch of Agarwood Huazhi Pills, which was marked as produced by Hebei Bianque Pharmaceutical Co., Ltd., did not meet the regulations, and the non-compliance items were the difference in loading.

  Three batches of Huoxiangzhengqi water produced by the Jiangxi Provincial Institute for Drug Inspection and Testing, marked as Sichuan Tianfu Kangda Pharmaceutical Group Fuqing Pharmaceutical Co., Ltd. and Taiji Group Sichuan Nanchong Pharmaceutical Co., Ltd. did not meet the regulations, and the non-compliant items were: amount of methanol.

  After inspection by Guangdong Provincial Institute of Drug Control, one batch of Longze Xiongdan Capsules marked as produced by Changchun Puhua Pharmaceutical Co., Ltd. did not meet the requirements, and the non-compliant items were microbial limits.

  According to the inspection of China National Institute for Food and Drug Control, the three batches of chrysanthemums marked as the production of Yancheng Traditional Chinese Medicine Pieces Co., Ltd. did not meet the regulations, and the items that did not meet the regulations were banned pesticide residues.

  After inspection by Gansu Provincial Institute for Drug Inspection, a batch of madder labeled as produced by Yunnan Jian'antang Biotechnology Co., Ltd. did not meet the regulations, and the non-conforming items included traits and identification; labeled as produced by Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co., Ltd. The 2 batches of madder did not meet the regulations, and the non-compliance items included traits, identification, total ash, acid-insoluble ash, and leaching.

  After inspection by the China National Institute for Food and Drug Control, a batch of comfrey labeled as produced by Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co., Ltd. did not meet the requirements, and the non-conforming items were content determination; labeled as produced by Zhengzhou Ruilong Pharmaceutical Co., Ltd. The 6 batches of comfrey do not meet the regulations, and the items that do not meet the regulations are traits.

  For the above-mentioned drugs that do not meet the regulations, the drug supervision and administration department has required relevant enterprises and units to take risk control measures such as suspension of sales and use, recalls, etc., to investigate the reasons for non-compliance and make rectifications.

  The State Drug Administration requires the relevant provincial drug supervision and administration departments to organize investigations into the suspected illegal activities of the above-mentioned enterprises and units in accordance with the "Pharmaceutical Administration Law of the People's Republic of China", and to disclose the results of the investigation and punishment according to regulations.

(Zhongxin Finance)